Risk Factors for Leukopenia with Valganciclovir Prophylaxis in CMV High Risk Cardiothoracic Transplant Recipients

被引：0
|
作者：
Brueckner, A. J. [1 ]
Doligalski, C. T. [1 ]
Logan, A. T. [1 ]
机构：
[1] Tampa Gen Hosp, Pharm, Tampa, FL 33606 USA
来源：
JOURNAL OF HEART AND LUNG TRANSPLANTATION | 2017年 / 36卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1122
引用
收藏
页码：S365 / S366
页数：2
相关论文
共 50 条
  • [1] Incidence and Risk Factors for Leukopenia in Kidney Transplant Recipients Receiving Valganciclovir for Cytomegalovirus Prophylaxis
    Liang, Xinyun
    Famure, Olusegun
    Li, Yanhong
    Kim, S. Joseph
    PROGRESS IN TRANSPLANTATION, 2018, 28 (02) : 124 - 133
  • [2] Valganciclovir is effective prophylaxis for CMV in high risk renal transplant recipients.
    Baillie, GM
    Ashcraft, EE
    Taber, DJ
    Stone, SS
    Emovon, O
    Rogers, J
    Afzal, F
    Lin, A
    Rajagopalan, PR
    Baliga, PK
    Chavin, KD
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 377A - 377A
  • [3] Incidence and Risk Factors for Leukopenia in Kidney Transplant Recipients Receiving Valganciclovir for Cytomegalovirus Prophylaxis.
    Liang, C.
    Famure, O.
    Li, Y.
    Kim, J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 319 - 319
  • [4] Incidence of CMV Disease in High-Risk Liver Transplant Recipients on Low Dose Valganciclovir Prophylaxis
    Tischer, S.
    Park, J.
    Stuckey, L.
    Kaul, D.
    Sonnenday, C.
    Fontana, R.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 221 - 222
  • [5] Utilization of a CMV T Cell Immunity Panel in Directing Duration of Valganciclovir Prophylaxis in CMV High Risk Kidney Transplant Recipients
    Ray, A.
    Garner, B.
    Klein, C.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2023, 23 (06) : S793 - S793
  • [6] Standard versus Reduced-Dose Valganciclovir CMV Prophylaxis in High-Risk Liver Transplant Recipients
    Dann, J.
    Geyston, J.
    Majmundar, D.
    Haywood, S.
    Shoemaker, C.
    Pelletier, S.
    Wentworth, B.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2023, 23 (06) : S395 - S395
  • [7] Valganciclovir for CMV prophylaxis in paediatric transplant recipients.
    Wiesmayr, S
    Stelzmueller, I
    Jungraithmayr, T
    Mark, W
    Larcher, C
    Margreiter, R
    Zimmerhackl, L
    Bonatti, H
    AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 355 - 355
  • [8] Valganciclovir as CMV prophylaxis in pediatric transplant recipients.
    Bonatti, H
    Wiesmayr, S
    Junngraithmayr, TC
    Margreiter, R
    Zimmerhackl, LB
    PEDIATRIC TRANSPLANTATION, 2005, 9 : 98 - 98
  • [9] CMV Infection Risk Factors and Viral Dynamics After Valganciclovir Prophylaxis: 10 Years of Experience in Lung Transplant Recipients
    Fernandez, Sarela Garcia-Masedo
    Laporta, Rosalia
    Fadul, Christian Garcia
    Perez, Myriam Aguilar
    Pedroche, Jorge Anel
    de Sevilla, Raquel Sanabrias Fernandez
    Royuela, Ana
    Romero, Isabel Sanchez
    Gil, Maria Piedad Ussetti
    MICROORGANISMS, 2024, 12 (11)
  • [10] The Risk of Leukopenia with Universal vs. Preemptive Prophylaxis Strategies in Heart Transplant Recipients at Intermediate Risk for CMV Complications
    Morris, A.
    Flattery, M.
    Ortega-Legaspi, J.
    Devore, A.
    Alexy, T.
    Shah, P.
    Nair, K.
    Cole, R. T.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2021, 40 (04): : S117 - S117
12345